184 related articles for article (PubMed ID: 17603402)
21. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Aboujaoude E; Barry JJ; Gamel N
J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
[TBL] [Abstract][Full Text] [Related]
22. Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density.
Wolmarans de W; Brand L; Stein DJ; Harvey BH
Behav Brain Res; 2013 Nov; 256():545-53. PubMed ID: 24013013
[TBL] [Abstract][Full Text] [Related]
23. Comparing escitaloipram with sertraline for obsessive and compulsive symptoms in patients with obsessive compulsive disorder: A comparative double blind clinical trial.
Mowla A; Modarresi F; Dastgheib SA
Asian J Psychiatr; 2018 Dec; 38():92-95. PubMed ID: 29158148
[TBL] [Abstract][Full Text] [Related]
24. Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy.
Stein DJ; Carey PD; Lochner C; Seedat S; Fineberg N; Andersen EW
CNS Spectr; 2008 Jun; 13(6):492-8. PubMed ID: 18567973
[TBL] [Abstract][Full Text] [Related]
25. Overvalued ideation as a predictor of fluvoxamine response in patients with obsessive-compulsive disorder.
Neziroglu F; Pinto A; Yaryura-Tobias JA; McKay D
Psychiatry Res; 2004 Jan; 125(1):53-60. PubMed ID: 14967552
[TBL] [Abstract][Full Text] [Related]
26. Impact of brain-derived neurotrophic factor Val66Met polymorphism and response to escitalopram or paroxetine in obsessive-compulsive disorder.
Harika-Germaneau G; Langbour N; Patri S; Solinas M; Chatard A; Millet B; Hashemian F; Pérault-Pochat MC; Jaafari N; Lafay-Chebassier C
CNS Spectr; 2022 Oct; 27(5):645-651. PubMed ID: 34313207
[TBL] [Abstract][Full Text] [Related]
27. Paroxetine treatment of compulsive hoarding.
Saxena S; Brody AL; Maidment KM; Baxter LR
J Psychiatr Res; 2007 Sep; 41(6):481-7. PubMed ID: 16790250
[TBL] [Abstract][Full Text] [Related]
28. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
29. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale.
Tolin DF; Abramowitz JS; Diefenbach GJ
J Clin Psychiatry; 2005 Dec; 66(12):1549-57. PubMed ID: 16401156
[TBL] [Abstract][Full Text] [Related]
30. High-dose escitalopram for the treatment of obsessive-compulsive disorder.
Rabinowitz I; Baruch Y; Barak Y
Int Clin Psychopharmacol; 2008 Jan; 23(1):49-53. PubMed ID: 18090508
[TBL] [Abstract][Full Text] [Related]
31. A randomized, open-label pilot trial of selective serotonin reuptake inhibitors on neuropsychological functions in patients with obsessive compulsive disorder.
Brar J; Sidana A; Chauhan N; Bajaj MK
J Psychiatr Res; 2022 Jul; 151():439-444. PubMed ID: 35598501
[TBL] [Abstract][Full Text] [Related]
32. New pharmacotherapeutic approaches to obsessive-compulsive disorder.
Figee M; Denys D
CNS Spectr; 2009 Feb; 14(2 Suppl 3):13-23. PubMed ID: 19238126
[TBL] [Abstract][Full Text] [Related]
33. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.
Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC
Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119
[TBL] [Abstract][Full Text] [Related]
34. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
[TBL] [Abstract][Full Text] [Related]
35. The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series.
Bergman J; Pashinian A; Weizman A; Poyurovsky M
Int Clin Psychopharmacol; 2014 Sep; 29(5):263-5. PubMed ID: 24810250
[TBL] [Abstract][Full Text] [Related]
36. Preschool children with obsessive-compulsive disorder and fluoxetine treatment.
Ercan ES; Kandulu R; Akyol Ardic U
Eur Child Adolesc Psychiatry; 2012 Mar; 21(3):169-72. PubMed ID: 22271063
[TBL] [Abstract][Full Text] [Related]
37. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness of high-dose escitalopram in the treatment of patients suffering from schizophrenia with comorbid obsessive-compulsive disorder: an open-label study.
Rubin-Kahana DS; Shelef A; Weizman A; Gothelf D; Timinski I; Spivak B; Stryjer R
Int Clin Psychopharmacol; 2019 Jul; 34(4):179-183. PubMed ID: 31058717
[TBL] [Abstract][Full Text] [Related]
39. Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia.
Poyurovsky M; Kriss V; Weisman G; Faragian S; Kurs R; Schneidman M; Fuchs C; Weizman A; Weizman R
J Clin Psychiatry; 2003 Nov; 64(11):1300-7. PubMed ID: 14658943
[TBL] [Abstract][Full Text] [Related]
40. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder.
Robert S; Hamner MB; Ulmer HG; Lorberbaum JP; Durkalski VL
J Clin Psychiatry; 2006 Oct; 67(10):1522-6. PubMed ID: 17107242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
